Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Inhaled Ciclesonide Improves Asthma Control: Presented at ACAAI - (DGDispatch)
    Efficacy of Aqueous Triamcinolone Acetonide in Allergic Rhinitis Not Affected by Gender: Presented at ACAAI - (DGDispatch)
    FDA Approves a C1-Esterase Inhibitor for Abdominal Attacks, Facial Swelling Associated With HAE - (DGNews)
    FDA Approves Bepotastine Besilate Solution for Ocular Itching Associated With Allergies - (DGNews)
    FDA Approves Levocetirizine Dihydrochloride for Paediatric Nasal Allergies - (DGNews)

    News archive

     Recent webcasts/CME - Allergy Other
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • Advances in Hereditary Angioedema Treatment: Considerations, Criteria & the New Therapy Options for Treatment & Prevention of HAE Attacks
      Sublingual Immunotherapy (SLIT) for Allergic Rhinitis The Latest Evidence
      Update in Hereditary Angioedema: A Disease in Rapid Evolution

      Webcasts/CME archive

       Recent cases - Allergy Other
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Anaphylaxis Following Intravenous Fluorescein Angiography in a Vitreoretinal Clinic: Report of 4 Cases
        Acute Allergic Reaction due to Milk Proteins Contaminating Lactose Added to Corticosteroid for Injection
        Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
        Anaphylactic Reaction to Camomile Tea

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        FDA Approves New Chewable Formulation of Allergy Medication Zyrtec (Cetirizine)

        Grape-Flavored Chewable Tablets Offer Efficacy and Convenience for Young Allergy Sufferers

        NEW YORK, NY -- March 18, 2004 -- Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of ZyrtecŪ (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.

        "This new chewable formulation provides more convenience and flexibility for a trusted antihistamine," said Gail Shapiro, MD, Senior Partner, Allergist, Northwest Asthma and Allergy Center, Clinical Professor of Pediatrics, University of Washington School of Medicine and past President of the American Academy of Allergy, Asthma and Immunology. "The chewable option will appeal to physicians, parents, and patients. It offers physicians another option to better meet our patient's individual needs; for parents it offers easy administration; for patients it offers Zyrtec's 24-hour symptom relief in a pleasant tasting, easy-to-chew tablet."

        The grape-flavored tablets are formulated to be taken once daily with or without food or water. They will be available in 5 mg and 10 mg doses to allow physicians the flexibility of prescribing the proper dose for children of different ages.

        Zyrtec is the number-one prescribed antihistamine by pediatricians and allergists(1). The new chewable formulation, which can be used by children as young as two years old, provides physicians with another Zyrtec option for their pediatric patients. Zyrtec syrup is available for babies as young as six months with year-round allergies or continuing hives. Zyrtec Chewable Tablets are bioequivalent to Zyrtec tablets and offer the same efficacy as Zyrtec tablets and syrup in a convenient formulation. The new chewable tablets will be available in a 30-tablet blister pack containing three cards of 10. Individual, foil-wrapped tablets can be easily removed by separating or bending the packaging perforation. As with all medications, Zyrtec Chewable Tablets should be kept out of the reach of children.

        "The development of the chewable formulation of Zyrtec underscores Pfizer and UCB Pharma's continued commitment to pediatric allergy patients," said Dr. Benjamin Kramer, senior medical director at Pfizer and a board certified allergist. "We believe that the concept of a convenient, good-tasting medication could help improve children's compliance with allergy medicine. And, increased compliance with allergy medicine may also improve health-related quality of life."

        Zyrtec syrup is the only antihistamine -- Rx or OTC -- FDA approved to treat indoor allergies and hives in infants down to the age of six months; no other antihistamine has received such FDA approval. With its proven history of indoor and outdoor symptom relief, no other allergy medication is approved to treat more allergies than Zyrtec.

        About ZYRTEC

        Zyrtec (cetirizine HCl) is a prescription antihistamine for the treatment of seasonal and perennial allergies as well as continuing hives in adults and children. It can be used in adults and children down to two years old, and for some of these allergies, it can even be used in infants as young as six months. In infants, 6 to 23 months old, side effects were like those of a sugar pill and included being cranky, fussy, and not able to sleep. Other side effects were feeling tired and looking uncomfortable. In studies with children aged 2 to 11 years old, side effects included drowsiness, headache, sore throat, and stomachache. Most were mild or moderate.

        Most children weren't bothered by side effects enough to stop taking Zyrtec. In studies with adults and children 12 years and older, the most common side effect was drowsiness; others included dry mouth and tiredness. Most were mild to moderate, but most people weren't bothered enough to stop taking Zyrtec.

        For additional information about allergies and for a copy of Zyrtec's full prescribing information, please visit the Zyrtec web site at http://www.zyrtec.com, or call 1-800-4-ZYRTEC.

        References:

        (1) IMS data for new prescriptions, Full year 2003


        SOURCE: Pfizer Inc



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send